

1 **Additional file 1**

Treatment	KRAS	RR (%)	mPFS (months)	mOS (months)
first-line				
FOLFOX/FOLFIRI/XELOX + Bev [1]	-	47	9.4	21.3
FOLFOX/FOLFIRI + C-mab [2]	WT	61	7.7	22.8
FOLFOX/FOLFIRI + P-mab [3]	WT	55	9.6	23.9
second-line				
FOLFOX/FOLFIRI + Bev [4]	-	22.7	7.3	12.9
FOLFIRI + Afibercept [5]	-	19.8	6.9	13.5
FOLFIRI + P-mab [6]	WT	35	5.9	14.5
further-line				
Irinotecan + C-mab [7]	WT	22.9	4.1	8.6
C-mab [8]	WT	19.8	4.4	10.0
P-mab [8]	WT	22.0	4.1	10.4
Regorafenib [9]	-	1.0	1.9	6.6
TAS102 [10]	-	1.6	2.0	7.1

2

3 Abbreviations; Bev, bevacizumab; C-mab, cetuximab; DCR, disease control rate;

4 FOLFIRI, infusional 5-fluorouracil/bolus+ folnic acid+ irinotecan; FOLFOX,

5 infusional 5-fluorouracil/bolus+ folnic acid+ oxaliplatin; mOS, median overall

6 survival; mPFS, median progression-free survival; NA, not available; P-mab,

7 panitumumab; RR, response rate; WT, wild type; XELOX, capecitabine+ oxaliplatin.

1 Additional references

- 2 1. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S,
3 Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: **Bevacizumab**
4 **in combination with oxaliplatin-based chemotherapy as first-line therapy in**
5 **metastatic colorectal cancer: a randomized phase III study.** *J Clin Oncol* 2008,
6 **26**:2013-9.
- 7 2. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F,
8 Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zube A, Koralewski P:
9 **Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the**
10 **first-line treatment of metastatic colorectal cancer.** *J Clin Oncol* 2009, **27**:663-
11 71.
- 12 3. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y,
13 Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-
14 Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J:
15 **Randomized, phase III trial of panitumumab with infusional fluorouracil,**
16 **leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line**
17 **treatment in patients with previously untreated metastatic colorectal cancer:**
18 **the PRIME study.** *J Clin Oncol* 2010, **28**:4697-705.
- 19 4. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR,
20 Schwartz MA, Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200:
21 **Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin**
22 **(FOLFOX4) for previously treated metastatic colorectal cancer: results from**
23 **the Eastern Cooperative Oncology Group Study E3200.** *J Clin Oncol* 2007,
24 **25**:1539-44.

- 1 5. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff
2 P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A,
3 Castan R, Allegra C: **Addition of aflibercept to fluorouracil, leucovorin, and**
4 **irinotecan improves survival in a phase III randomized trial in patients with**
5 **metastatic colorectal cancer previously treated with an oxaliplatin-based**
6 **regimen.** *J Clin Oncol* 2012, **30**:3499-506.
- 7 6. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T,
8 Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L,
9 Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J:
10 **Randomized phase III study of panitumumab with fluorouracil, leucovorin,**
11 **and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line**
12 **treatment in patients with metastatic colorectal cancer.** *J Clin Oncol* 2010,
13 **28**:4706-13.
- 14 7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D,
15 Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: **Cetuximab**
16 **monotherapy and cetuximab plus irinotecan in irinotecan-refractory**
17 **metastatic colorectal cancer.** *N Engl J Med* 2004, **351**:337-45.
- 18 8. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A,
19 Tjulandin S, Zhang K, Murugappan S, Sidhu R: **Panitumumab versus cetuximab**
20 **in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic**
21 **colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-**
22 **inferiority phase 3 study.** *Lancet Oncol* 2014, **15**:569-79.
- 23 9. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y,
24 Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ,
25 Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent

1 D; CORRECT Study Group: **Regorafenib monotherapy for previously treated**
2 **metastatic colorectal cancer (CORRECT): an international, multicentre,**
3 **randomised, placebo-controlled, phase 3 trial.** *Lancet* 2013, **381**:303-12.

4 10. Yoshino T, Mayer R, Falcone. **Results of a multicenter, randomized, double-**
5 **blind, phase III study of TAS-102 vs. placebo, with best supportive care**
6 **(BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory**
7 **to standard therapies (RECOURSE) [abstract].** *Ann Oncol* 2014, **25**:s2.